Creative Bioarray Launches In Vitro Metabolic Stability to Support Accurate Predictions for The Stability of Compounds
Recently DDA pltform announced the release of its in vitro metabolic stability which can be applied to support accutate prediction of the stability of compounds.
New York, United States – December 11, 2020 /MarketersMedia/ —
DDA Platform, the division of Creative Bioarray, is an innovative biotechnology company focuses on developing high quality products and services in order to accelerate research in the field of phatmaceuticals, life science and clinical etc., recently DDA pltform announced the release of its in vitro metabolic stability which can be applied to support accutate prediction of the stability of compounds.
Due to poor metabolic stability, many compounds with good pharmacological properties have never become drugs. For example, drugs that are rapidly metabolized may not produce sufficient levels of exposure in the body, or drugs that are slowly metabolized may remain in the body for a longer period of time, resulting in adverse reactions.
Understanding the sensitivity of compounds to undergo biotransformation in vivo is essential for selecting drug candidates with good pharmacokinetic properties. The in vitro metabolic stability assay provided by the DDA platform can measure the intrinsic clearance (Clint) of a compound, thereby providing the key data needed to calculate other key pharmacokinetic parameters.
In order to accurately predict the stability of compounds in various organs of the human body, DDA platform provides a variety of in vitro test systems, including liver microsomes, liver cells, S9 fractions, blood and plasma, and recombinant enzymes in animals and animals. Human species.
Main features of DDA platform’s metabolic stability service:
. LC/MS method development for analytical test items
. Screening takes place at four optional time points (short-term, mid-term and long-term course options)
. Incubate with appropriate cofactors in a suitable test system (S9, microsomes, hepatocytes, recombinant CYP enzymes) and evaluate in triplicate at multiple time points, with additional repetitions for key samples
. Comparison of time and cofactor blank
. Incubate the labeled substrate as a positive control to check the metabolic capacity of the test system
. Data analysis
In which, Creative Bioarray’s hepatocyte stability assay can monitor the disappearance of substrates in the presence of liver cells. This assay can determine the fate of the drug in the body and calculate its clearance rate. Using liver cells from various species can help determine the species specificity of liver clearance and transform animal data into human scenarios.
“All the tests can be ordered separately, in combination or as an option for the key stability services provided in the drug candidate evaluation package to save costs.” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed that, “if you have any specific needs, our experts will customize solutions to support your research.”
About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.
Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: Shirley, NY 11967, USA
Phone: 16316197922
Website: https://dda.creative-bioarray.com/
Source: MarketersMedia
Release ID: 88989427
Copyright © 1999-2013 SproutNews.com
